Fig. 5.

Lithium chloride (LiCl) modulation of the 1.3-kb type IIb MyHC promoter and type IIb MyHC mRNA levels. C₂C₁₂ myocytes were harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I). DMSO (vehicle) or LiCl (10 mM) was added during the final 24 h of 3 days of differentiation. A: 1.3-kb type IIb MyHC promoter activity. Values are expressed as a percentage of control vehicle. B: type IIb MyHC mRNA levels. Values are expressed as a percentage of control vehicle and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control within same treatment, #P < 0.05 from control vehicle, $P < 0.05 from IGF-I vehicle.